TOP TEN perturbations for 38466_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38466_at
Selected probe(set): 202450_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38466_at (202450_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; metastatic) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, clear cell sarcoma, NOS; metastatic)
Relative Expression (log2-ratio):5.931512Number of Samples:2 / 2
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, leiomyosarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, clear cell sarcoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, clear cell sarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. |
glioma study 16 (BS-149) / normal astrocyte sample
Relative Expression (log2-ratio):5.2791014Number of Samples:2 / 3
| Experimental | glioma study 16 (BS-149) |
| Human glioma cell line BS149 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
| Control | normal astrocyte sample |
| Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, malignant peripheral nerve sheath tumor; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, fibromyxosarcoma; primary)
Relative Expression (log2-ratio):-4.960037Number of Samples:3 / 5
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, malignant peripheral nerve sheath tumor; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, malignant peripheral nerve sheath tumor of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, fibromyxosarcoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, fibromyxosarcoma of the soft tissue (subcutaneously implanted). |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, fibromyxosarcoma; primary)
Relative Expression (log2-ratio):-4.8706417Number of Samples:2 / 5
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, fibromyxosarcoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, fibromyxosarcoma of the soft tissue (subcutaneously implanted). |
pancreatic islet study 3 (re-differentiated; PPRF; 2d) / normal pancreatic islet sample
Relative Expression (log2-ratio):4.5561686Number of Samples:2 / 7
| Experimental | pancreatic islet study 3 (re-differentiated; PPRF; 2d) |
| Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 2 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0ug/ml. | |
| Control | normal pancreatic islet sample |
| Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation. |
Merkel cell carcinoma study 3 (metastatic) / normal skin tissue
Relative Expression (log2-ratio):-4.4092064Number of Samples:11 / 64
| Experimental | Merkel cell carcinoma study 3 (metastatic) |
| Metastatic tumor tissue from different metastatic sites (skin, lymph node, parotid gland) of patients with Merkel cell carcinoma of the skin. | |
| Control | normal skin tissue |
| Normal skin samples from healthy donors. |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, fibromyxosarcoma; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, dedifferentiated liposarcoma; primary)
Relative Expression (log2-ratio):4.3599167Number of Samples:5 / 5
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, fibromyxosarcoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, fibromyxosarcoma of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, dedifferentiated liposarcoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, dedifferentiated liposarcoma of the soft tissue (subcutaneously implanted). |
pancreatic islet study 3 (re-differentiated; PPRF; 4d) / normal pancreatic islet sample
Relative Expression (log2-ratio):4.3534536Number of Samples:2 / 7
| Experimental | pancreatic islet study 3 (re-differentiated; PPRF; 4d) |
| Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 4 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0ug/ml. | |
| Control | normal pancreatic islet sample |
| Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation. |
pancreatic islet study 3 (re-differentiated; PPRF; 6d) / normal pancreatic islet sample
Relative Expression (log2-ratio):4.2144613Number of Samples:2 / 7
| Experimental | pancreatic islet study 3 (re-differentiated; PPRF; 6d) |
| Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 6 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0 ug/ml. | |
| Control | normal pancreatic islet sample |
| Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation. |
prostate cancer study 8 (p. canc) / prostate cancer study 8 (ptasc)
Relative Expression (log2-ratio):-4.174858Number of Samples:3 / 2
| Experimental | prostate cancer study 8 (p. canc) |
| CD26+ FACS sorted prostate neoplasm cell (p. canc) samples from patients with primary prostate cancer collected after radical prostatectomy. | |
| Control | prostate cancer study 8 (ptasc) |
| CD90+ FACS sorted prostate tumor-associated stromal cell (ptasc) samples from patients with primary prostate cancer collected after radical prostatectomy. |